Alvimopan, a perpherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery
- First Online:
- Cite this article as:
- Viscusi, E., Goldstein, S., Witkowski, T. et al. Surg Endosc (2006) 20: 537. doi:10.1007/s00464-006-3025-5
[Surg Endosc (2006) 20: 64–70, DOI: 10.1007/s00464-005-0104-y]
This was a randomized, double-blind, placebo-controlled, parallel-group, phase III trial (Study 14CL308) designed to evaluate the efficacy and safety of 6 and 12 mg alvimopan for the management of POI in patients undergoing BR or TAH.